@Article{or.2025.072443,
AUTHOR = {Tiffany Chen, Grace Kim, Yekta Rahimi, Monisha Kamdar, Eduardo Fernandez-Hernandez, Karrune Woan, Eric L. Tam, George Yaghmour},
TITLE = {Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives},
JOURNAL = {Oncology Research},
VOLUME = {34},
YEAR = {2026},
NUMBER = {3},
PAGES = {--},
URL = {http://www.techscience.com/or/v34n3/66275},
ISSN = {1555-3906},
ABSTRACT = {Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring <i>KMT2A</i> rearrangements (<i>KMT2A</i>r) and <i>NPM1</i> mutations (<i>NPM1</i>m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several other agents in development, ziftomenib (KO-539), bleximenib (JNJ-75276617), and icovamenib (BMF-219). We also focused our discussion on future directions to include resistance mechanisms, biomarker identification and monitoring strategies, and combination therapies. Menin inhibition is now being clinically integrated into relapsed/refractory and frontline treatment settings.},
DOI = {10.32604/or.2025.072443}
}